

INTRODUCTION .....	XXIV
STUDY GOAL AND OBJECTIVES .....	XXIV
REASONS FOR DOING THE STUDY .....	XXIV
INTENDED AUDIENCE.....	XXV
SCOPE OF REPORT .....	XXV
METHODOLOGY .....	XXVI
INFORMATION SOURCES.....	XXVI
AUTHOR’S CREDENTIALS .....	XXVII
RELATED REPORTS FROM BCC RESEARCH .....	XXVII
BCC ONLINE SERVICES.....	XXVII
DISCLAIMER .....	XXVIII
 SUMMARY.....	 XXIX
<i>SUMMARY TABLE GLOBAL ORPHAN DRUGS DEMAND BY VALUE,     THROUGH 2011 (\$ MILLIONS)</i> .....	 XXIX
<i>SUMMARY FIGURE GLOBAL ORPHAN DRUGS DEMAND BY VALUE,     2005-2011 (\$ MILLIONS)</i> .....	 XXX
 OVERVIEW .....	 1
DEFINITION OF AN ORPHAN DRUG .....	1
HISTORY OF ORPHAN DRUG LEGISLATION .....	1
FIRST LEGISLATION ON ORPHAN DRUGS.....	1
Amendments to the ODA .....	1
Bills Passed in 2002 Increased Funding and Established the Office of Rare Diseases .....	2
Orphan Drug Legislation—Global Status .....	2
INCENTIVES FOR ORPHAN DRUG DEVELOPMENT .....	2
THE NEED FOR INCENTIVES .....	2
<i>TABLE 1 NUMBER OF ORPHAN DRUG DESIGNATIONS AND     APPROVALS PER YEAR BY U.S. FDA, 1983-2006</i> .....	 3
CONCERNS ABOUT THE ORPHAN DRUG ACT .....	4
COST-EFFECTIVENESS.....	4
MARKET EXCLUSIVITY VERSUS PATENT PROTECTION .....	4
MARKET SIZE AND KEY PLAYERS .....	5
<i>TABLE 2 TOP 10 COMPANIES IN THE ORPHAN DRUG MARKET AND     THEIR MARKET SHARES (%)</i> .....	 6
CHALLENGES FOR EFFECTIVE USAGE OF THE ORPHAN DRUG ACT .....	6
THE ORPHAN DRUG ACT—A BONUS FOR BIOTECH .....	7
PROFITABILITY OF ORPHAN DRUGS .....	7
MARKET EXCLUSIVITY.....	7
NO REGULATORY RESTRICTIONS ON PRICING.....	8
OFF-LABEL USE.....	8

WORLDWIDE INDUSTRY STRUCTURE.....	9
GLOBAL AND REGIONAL SALES OF ORPHAN DRUGS.....	9
<i>TABLE 3 REGIONAL SALES OF ORPHAN DRUGS, THROUGH 2011</i>	
<i>(\$ MILLIONS)</i> .....	10
<i>FIGURE 1 REGIONAL SALES AND FORECASTS FOR ORPHAN</i>	
<i>DRUGS, 2005-2011 (\$ MILLIONS)</i> .....	10
CATEGORIES OF ORPHAN DRUG MARKET PLAYERS.....	10
INDUSTRY TRENDS BY SPONSOR TYPES.....	11
ANALYSIS OF ORPHAN DRUG APPROVALS BY SPONSOR	
CATEGORIES.....	11
<i>FIGURE 2 ANALYSIS OF ORPHAN DRUG APPROVALS BY SPONSOR</i>	
<i>TYPES (%)</i> .....	12
ORPHAN DRUG DESIGNATIONS AND APPROVALS BY	
COMPANIES .....	12
<i>TABLE 4 COMPANIES WITH MORE THAN 15 ORPHAN DRUG</i>	
<i>DESIGNATIONS, 1983-2006</i> .....	13
<i>TABLE 5 COMPANIES WITH MORE THAN FIVE ORPHAN DRUG</i>	
<i>APPROVALS, 1983-2006</i> .....	14
ORPHAN DRUG REVENUES BY SPONSOR TYPES.....	15
BIG PHARMA VERSUS BIOTECH COMPANIES.....	15
<i>TABLE 6 SALES OF LEADING ORPHAN DRUGS—BIG PHARMA</i>	
<i>VERSUS BIOTECH COMPANIES, 2006</i> .....	15
<i>TABLE 6 (CONTINUED)</i> .....	16
<i>TABLE 6 (CONTINUED)</i> .....	17
ORPHAN DRUGS — A STRATEGIC CHOICE BY BIOTECH	
COMPANIES.....	17
LEADING PLAYERS IN THE GLOBAL ORPHAN DRUG MARKET .....	18
<i>TABLE 7 LEADING COMPANIES IN THE ORPHAN DRUG MARKET</i>	
<i>AND THEIR REVENUES FROM ORPHAN DRUGS</i> .....	19
PARTNERSHIP STRATEGIES IN THE ORPHAN DRUG MARKET.....	19
<i>TABLE 8 ANALYSIS OF PARTNERSHIP STRATEGIES IN THE CASE</i>	
<i>OF LEADING ORPHAN DRUGS</i> .....	20
<i>TABLE 8 (CONTINUED)</i> .....	21
ORPHANS TO BLOCKBUSTERS—KEY GROWTH FACTORS .....	22
MULTIPLE ORPHAN INDICATIONS .....	22
<i>TABLE 9 BLOCKBUSTER ORPHAN DRUGS WITH APPROVALS FOR</i>	
<i>MULTIPLE INDICATIONS</i> .....	23
<i>TABLE 9 (CONTINUED)</i> .....	24
OFF-LABEL USAGES/APPROVAL FOR NON-ORPHAN	
INDICATIONS.....	24
LACK OF COMPETITION FROM BIOGENERICS.....	24
<i>TABLE 10 BIOLOGIC BLOCKBUSTERS AND THEIR MARKET</i>	
<i>EXCLUSIVITY STATUS, 2006</i> .....	25
<i>TABLE 10 (CONTINUED)</i> .....	26

SYNTHETIC PHARMACEUTICALS AS BLOCKBUSTERS .....	26
PHARMACOGENOMICS AND ITS POTENTIAL IMPACT ON THE ORPHAN DRUG ACT .....	27
PRODUCTS .....	28
ORPHAN DRUGS APPROVED BY THE U.S. FDA (1983–2006) .....	28
ORPHAN DRUG DESIGNATIONS AND APPROVALS SINCE 1983.....	28
<i>TABLE 11 NUMBER OF ORPHAN DESIGNATIONS AND APPROVALS     BY U.S. FDA 1983-2006</i> .....	28
<i>TABLE 11 (CONTINUED)</i> .....	29
<i>TABLE 12 DETAILS OF ORPHAN DRUG MARKETING APPROVALS     BY U.S. FDA, 1983-2006 (TOTAL NO. OF ORPHAN DRUG     APPROVALS EACH YEAR</i> .....	29
<i>TABLE 12 (CONTINUED)</i> .....	30
PERCENTAGE OF ORPHAN DRUG APPROVALS IN OVERALL DRUG APPROVALS BY THE U.S. FDA IN THE PAST DECADE.....	31
<i>TABLE 13 DRUGS AND BIOLOGICS APPROVED BY THE FDA FROM     1990 TO 2006, A COMPARISON OF PRODUCTS WITH AND     WITHOUT ORPHAN DRUG STATUS</i> .....	31
ORPHAN DRUGS WITH SALES EXCEEDING \$200 MILLION IN 2006 .....	31
<i>TABLE 14 ORPHAN DRUGS WITH GLOBAL SALES EXCEEDING \$200     MILLION, 2006</i> .....	32
<i>TABLE 14 (CONTINUED)</i> .....	33
DETAILED ANALYSIS OF SUCCESSFULL AND PROMISING ORPHAN DRUGS.....	33
AVONEX.....	34
Additional Approvals Gained.....	34
Marketing Strategies.....	34
Sales of Avonex .....	35
<i>TABLE 15 GLOBAL SALES OF AVONEX, 2000–2006 (\$ MILLIONS)</i> .....	35
BETASERON .....	36
Additional Approvals Gained.....	36
Marketing Strategies.....	36
Sales of Betaseron .....	37
<i>TABLE 16 GLOBAL SALES OF BETASERON, 2000–2006 (\$ MILLIONS)</i> .....	37
BOTOX.....	38
Additional Approvals Gained.....	38
Marketing Strategies.....	38
Sales of Botox.....	39
<i>TABLE 17 GLOBAL SALES OF BOTOX FOR THERAPEUTIC AND     COSMETIC USAGES, 2002–2006 (\$ MILLIONS)</i> .....	39
CEREZYME/CEREDASE .....	39
Additional Approvals and Marketing Strategies .....	40
Sales of Cerezyme.....	40

<i>TABLE 18 GLOBAL SALES OF CERAZYME, 2000–2006 (\$ MILLIONS)</i> .....	40
COPAXONE.....	40
Marketing Strategies.....	41
Sales of Copaxone .....	41
<i>TABLE 19 GLOBAL SALES OF COPAXONE, 2002–2006 (\$ MILLIONS)</i> .....	41
ENBREL.....	42
Additional Indications .....	42
Market Strategies.....	43
Sales of Enbrel .....	43
<i>TABLE 20 U.S. AND INTERNATIONAL SALES OF ENBREL, 2003–2006 (\$ MILLIONS)</i> .....	43
EPOGEN.....	44
Recent Threats to Market Share.....	44
Sales of Epogen .....	44
<i>TABLE 21 GLOBAL SALES OF EPOGEN, 2000-2006 (\$ MILLIONS)</i> .....	45
ERBITUX.....	45
Additional Indications .....	45
Market Strategies and Threats.....	46
Sales of Erbitux .....	46
<i>TABLE 22 GLOBAL SALES OF ERBITUX, 2004–2006 (\$ MILLIONS)</i> .....	46
GLEEVEC.....	47
Approval for Multiple Indications.....	47
Market Strategy .....	47
Sales of Gleevec .....	48
<i>TABLE 23 GLOBAL SALES OF GLEEVEC, 2001–2006 (\$ MILLIONS)</i> .....	48
INTRON A/PEGINTRON .....	48
Market Strategy .....	49
Sales of Intron A/PegIntron .....	49
<i>TABLE 24 GLOBAL SALES OF INTRON A/PEGINTRON, 2004-2006 (\$ MILLIONS)</i> .....	49
KOGENATE .....	50
Sales of Kogenate.....	50
<i>TABLE 25 GLOBAL SALES OF KOGENATE, 2001–2006 (\$ MILLIONS)</i> .....	50
LAMICTAL.....	50
Sales of Lamictal .....	51
<i>TABLE 26 GLOBAL SALES OF LAMICTAL, 2001–2006 (\$ MILLIONS)</i> .....	52
NEUPOGEN/NEULASTA .....	52
Additional Indications .....	52
Marketing Strategies.....	53
Sales of Neupogen/Neulasta.....	53
<i>TABLE 27 GLOBAL SALES OF NEUPOGEN/NEULASTA, 2001–2006 (\$ MILLIONS)</i> .....	53
NOVOSEVEN.....	54
Sales of NovoSeven.....	54

<i>TABLE 28 GLOBAL SALES OF NOVOSEVEN, 2000–2006 (\$ MILLIONS)</i> .....	54
PROGRAF.....	54
Additional Indications .....	55
Future Prospects.....	55
Sales of Prograf.....	55
REMICADE .....	56
Additional Approvals.....	56
Characteristics of Target Market.....	56
Sales of Remicade .....	57
<i>TABLE 29 GLOBAL SALES OF REMICADE, 2001–2006 (\$ MILLIONS)</i> .....	57
RITUXAN .....	57
Additional Indications .....	58
Characteristics of Market.....	58
Sales of Rituxan.....	59
<i>TABLE 30 GLOBAL SALES OF RITUXAN, 2000–2006 (\$ MILLIONS)</i> .....	59
TOPAMAX .....	60
Additional Indications .....	60
Sales of Topamax.....	60
<i>TABLE 31 GLOBAL SALES OF TOPAMAX, 2001–2006 (\$ MILLIONS)</i> .....	60
ZOMETA.....	61
Additional indications .....	61
Market Characteristics.....	61
Sales of Zometa .....	61
<i>TABLE 32 U.S. AND GLOBAL SALES OF ZOMETA, 2002–2006 (\$ MILLIONS)</i> .....	61
ORPHAN VACCINES.....	62
ORPHAN DRUG SALES BY TECHNOLOGY .....	62
ORPHAN BIOLOGICS .....	62
Global Sales and Forecasts of Orphan Biologics .....	63
<i>TABLE 33 SALES AND FORECASTS OF LEADING BIOLOGIC ORPHAN DRUGS, WORLDWIDE: THROUGH 2011 (\$ MILLIONS)</i> .....	63
<i>FIGURE 3 FORECASTS OF LEADING BIOLOGICAL ORPHAN DRUG SALES, WORLDWIDE, 2005-2011 (\$ MILLIONS)</i> .....	64
SUB-CLASSES OF ORPHAN BIOLOGICS.....	64
<i>TABLE 34 SALES AND FORECASTS OF LEADING MONOCLONAL ANTIBODY ORPHAN DRUG SALES, WORLDWIDE, THROUGH 2011 (\$ MILLIONS)</i> .....	65
<i>FIGURE 4 FORECAST OF LEADING MONOCLONAL ANTIBODY ORPHAN DRUG SALES, WORLDWIDE, 2005-2011 (\$ MILLIONS)</i> .....	65
<i>TABLE 35 GLOBAL SALES AND FORECASTS OF LEADING INTERFERONS/ INTERLEUKINS WITH ORPHAN DRUG STATUS, WORLDWIDE, THROUGH 2011 (\$ MILLIONS)</i> .....	66

<i>FIGURE 5 GLOBAL SALES AND FORECASTS OF LEADING INTERFERONS/ INTERLEUKINS WITH ORPHAN STATUS, WORLDWIDE, 2005-2011 (\$ MILLIONS)</i> .....	66
<i>TABLE 36 GLOBAL SALES AND FORECASTS OF LEADING GROWTH HORMONES WITH ORPHAN DRUG STATUS, WORLDWIDE, THROUGH 2011 (\$ MILLIONS)</i> .....	67
<i>FIGURE 6 GLOBAL SALES AND FORECASTS OF LEADING GROWTH HORMONES WITH ORPHAN DRUG STATUS, WORLDWIDE, 2005-2011 (\$ MILLIONS)</i> .....	67
<i>TABLE 37 GLOBAL SALES AND FORECASTS OF LEADING PLASMA PRODUCT ORPHAN DRUG SALES, WORLDWIDE, THROUGH 2011 (\$ MILLIONS)</i> .....	68
<i>FIGURE 7 FORECAST OF LEADING PLASMA PRODUCT ORPHAN DRUG SALES, WORLDWIDE, 2005-2011 (\$ MILLIONS)</i> .....	68
NON-BIOLOGIC ORPHAN DRUGS.....	69
<i>TABLE 38 GLOBAL SALES AND FORECASTS OF LEADING NON-BIOLOGIC ORPHAN DRUGS, WORLDWIDE, THROUGH 2011 (\$ MILLIONS)</i> .....	69
<i>FIGURE 8 GLOBAL SALES AND FORECASTS FOR NON-BIOLOGIC ORPHAN DUGS, WORLDWIDE, 2005-2011 (\$ MILLIONS)</i> .....	70
APPLICATIONS.....	71
CANCER.....	71
LEUKEMIAS.....	71
Acute Lymphocytic/Lymphoblastic Leukemia .....	72
Acute Myelogenous/Myelocytic Leukemia.....	72
Chronic Lymphocytic Leukemia .....	72
Chronic Myelocytic/Myelogenous Leukemia .....	73
LYMPHOMAS.....	73
Hodgkin’s Lymphoma.....	73
Non-Hodgkin’s Lymphoma.....	74
MULTIPLE MYELOMA .....	74
SOLID TUMORS.....	74
CANCER-RELATED CONDITIONS.....	75
<i>TABLE 39 ORPHAN DRUGS APPROVED BY U.S. FDA TO TREAT CANCER AND CANCER-RELATED CONDITIONS</i> .....	75
<i>TABLE 39 (CONTINUED)</i> .....	76
<i>TABLE 39 (CONTINUED)</i> .....	77
<i>TABLE 39 (CONTINUED)</i> .....	78
<i>TABLE 39 (CONTINUED)</i> .....	79
<i>TABLE 39 (CONTINUED)</i> .....	80
<i>TABLE 39 (CONTINUED)</i> .....	81
SALES OF LEADING ORPHAN PRODUCTS TO TREAT CANCER AND CANCER-RELATED CONDITIONS .....	81

<i>TABLE 40 THE MARKET FOR LEADING ORPHAN DRUGS TO TREAT CANCER: WORLDWIDE, THROUGH 2011 (\$ MILLIONS)</i> .....	82
<i>FIGURE 9 THE MARKET FOR LEADING ORPHAN DRUGS TO TREAT CANCER AND CANCER RELATED CONDITIONS, WORLDWIDE, 2005-2011 (\$ MILLIONS)</i> .....	82
CARDIOVASCULAR DISEASES AND BLOOD DISORDERS.....	83
ANEMIA .....	83
HYPERCALCEMIA.....	83
HYPERTENSION .....	83
HYPOTENSION.....	84
NEUTROPENIA.....	84
TACHYARRHYTHMIAS/TACHYCARDIA.....	84
THROMBOCYTHEMIA.....	84
THROMBOCYTOPENIA .....	85
ORPHAN DRUGS APPROVED TO TREAT CARDIOVASCULAR DISEASES AND BLOOD DISORDERS.....	85
<i>TABLE 41 APPROVED ORPHAN DRUGS TO TREAT CARDIOVASCULAR DISEASES AND BLOOD DISORDERS</i> .....	85
<i>TABLE 41 (CONTINUED)</i> .....	86
<i>TABLE 41 (CONTINUED)</i> .....	87
SALES OF LEADING ORPHAN PRODUCTS TO TREAT CARDIOVASCULAR DISEASES AND BLOOD DISORDERS: WORLDWIDE, THROUGH 2011.....	87
<i>TABLE 42 THE MARKET FOR LEADING ORPHAN DRUGS TO TREAT CARDIOVASCULAR DISEASES AND BLOOD DISORDERS, THROUGH 2011 (\$ MILLIONS)</i> .....	88
<i>FIGURE 10 THE MARKET FOR LEADING ORPHAN DRUGS TO TREAT CARDIOVASCULAR DISEASES AND BLOOD DISORDERS, WORLDWIDE, 2005-2011 (\$ MILLIONS)</i> .....	88
GASTROINTESTINAL DISEASES .....	88
CHOLELITHIASIS .....	89
ESOPHAGEAL VARICES .....	89
ORPHAN PRODUCTS APPROVED TO TREAT GASTROINTESTINAL DISEASES .....	89
<i>TABLE 43 APPROVED ORPHAN DRUGS TO TREAT GASTROINTESTINAL DISEASES</i> .....	89
<i>TABLE 43 (CONTINUED)</i> .....	90
SALES OF LEADING ORPHAN PRODUCTS TO TREAT GASTROINTESTINAL DISEASES .....	90
GENETIC DISEASES AND DISORDERS .....	90
ALPHA-1 PROTEINASE DEFICIENCY .....	91
FABRY DISEASE.....	91
GAUCHER DISEASE .....	91
HEMOPHILIA.....	92

MUCOPOLYSACCHARIDOSIS .....	92
TYROSINEMIA.....	93
ORPHAN PRODUCTS APPROVED TO TREAT GENETIC DISEASES AND DISORDERS .....	94
<i>TABLE 44 APPROVED ORPHAN DRUGS TO TREAT GENETIC DISEASES AND DISORDERS.....</i>	<i>94</i>
<i>TABLE 44 (CONTINUED).....</i>	<i>95</i>
<i>TABLE 44 (CONTINUED).....</i>	<i>96</i>
SALES OF LEADING ORPHAN PRODUCTS TO TREAT GENETIC DISEASES AND DISORDERS .....	96
<i>TABLE 45 THE MARKET FOR LEADING ORPHAN DRUGS TO TREAT GENETIC DISEASES AND DISORDERS, WORLDWIDE, 2005-2011 (\$ MILLIONS).....</i>	<i>97</i>
<i>FIGURE 11 THE MARKET FOR LEADING ORPHAN DRUGS TO TREAT GENETIC DISEASES AND DISORDERS, WORLDWIDE, 2005-2011 (\$ MILLIONS).....</i>	<i>97</i>
IMMUNE DISEASES .....	98
COMMON VARIABLE IMMUNODEFICIENCY .....	98
INTERSTITIAL CYSTITIS.....	98
JUVENILE RHEUMATOID ARTHRITIS .....	99
ORGAN TRANSPLANT REJECTION .....	99
ORPHAN PRODUCTS APPROVED TO TREAT IMMUNE AND AUTOIMMUNE DISEASES AND TRANSPLANT REJECTION .....	100
<i>TABLE 46 APPROVED ORPHAN DRUGS TO TREAT IMMUNE AND AUTOIMMUNE DISEASES/TRANSPLANT REJECTION .....</i>	<i>100</i>
SALES OF LEADING ORPHAN PRODUCTS TO TREAT IMMUNE AND AUTOIMMUNE DISEASES AND TRANSPLANT REJECTION .....	100
<i>TABLE 47 THE MARKET FOR LEADING ORPHAN DRUGS IN THE IMMUNE DISEASES SECTOR, WORLDWIDE, THROUGH 2011 (\$ MILLIONS).....</i>	<i>101</i>
<i>FIGURE 12 THE MARKET FOR LEADING ORPHAN DRUGS IN THE IMMUNE DISEASES SECTOR, WORLDWIDE, 2005-2011 (\$ MILLIONS).....</i>	<i>101</i>
INFECTIOUS DISEASES .....	101
ACQUIRED IMMUNE DEFICIENCY SYNDROME .....	102
CRYPTOCOCCAL MENINGITIS .....	102
CRYPTOSPORIDIOSIS .....	102
CYTOMEGALOVIRUS RETINITIS.....	103
GIARDIASIS.....	103
HYDATID DISEASE.....	103
KERATOCONJUNCTIVITIS .....	104
LEISHMANIASIS .....	104



LEPROSY .....	104
MALARIA .....	105
NEUROCYSTICERCOSIS.....	105
PNEUMOCYSTIC CARINII PNEUMONIA .....	105
RESPIRATORY SYNCYTIAL VIRUS.....	106
TUBERCULOSIS.....	106
ORPHAN PRODUCTS APPROVED TO TREAT INFECTIOUS DISEASES.....	106
<i>TABLE 48 APPROVED ORPHAN DRUGS TO TREAT INFECTIOUS DISEASES .....</i>	<i>107</i>
<i>TABLE 48 (CONTINUED).....</i>	<i>108</i>
<i>TABLE 48 (CONTINUED).....</i>	<i>109</i>
SALES OF LEADING ORPHAN PRODUCTS TO TREAT INFECTIOUS DISEASES.....	109
<i>TABLE 49 THE MARKET FOR LEADING ORPHAN DRUGS TO TREAT INFECTIOUS DISEASES, WORLDWIDE, THROUGH 2011 (\$ MILLIONS).....</i>	<i>110</i>
<i>FIGURE 13 THE MARKET FOR LEADING ORPHAN DRUGS TO TREAT INFECTIOUS DISEASES, WORLDWIDE, 2005-2011 (\$ MILLIONS).....</i>	<i>110</i>
INFLAMMATORY DISEASES .....	110
ANKYLOSING SPONDYLITIS.....	111
CROHN'S DISEASE .....	111
ORPHAN PRODUCTS APPROVED TO TREAT INFLAMMATORY DISEASES .....	111
<i>TABLE 50 APPROVED ORPHAN DRUGS TO TREAT INFLAMMATORY DISEASES .....</i>	<i>112</i>
SALES OF LEADING ORPHAN PRODUCTS TO TREAT INFLAMMATORY DISEASES .....	112
<i>TABLE 51 THE MARKET FOR LEADING ORPHAN DRUGS TO TREAT INFLAMMATORY DISEASES, WORLDWIDE, THROUGH 2011 (\$ MILLIONS).....</i>	<i>112</i>
<i>FIGURE 14 THE MARKET FOR LEADING ORPHAN DRUGS TO TREAT INFLAMMATORY DISEASES, WORLDWIDE, 2005-2011 (\$ MILLIONS).....</i>	<i>113</i>
NEUROLOGICAL DISEASES AND DISORDERS.....	113
BLEPHAROSPASM.....	113
DYSTONIA.....	114
LENNOX-GASTAUT SYNDROME.....	114
MULTIPLE SCLEROSIS.....	114
NARCOLEPSY/CATAPLEXY.....	115
STRABISMUS.....	115
ORPHAN PRODUCTS APPROVED TO TREAT NEUROLOGICAL DISEASES AND DISORDERS.....	115

<i>TABLE 52 APPROVED ORPHAN DRUGS FOR NEUROLOGICAL DISEASES AND DISORDERS</i> .....	116
<i>TABLE 52 (CONTINUED)</i> .....	117
SALES OF LEADING ORPHAN PRODUCTS TO TREAT NEUROLOGICAL DISEASES AND DISORDERS.....	117
<i>TABLE 53 THE MARKET FOR LEADING ORPHAN DRUGS TO TREAT NEUROLOGICAL DISEASES AND DISORDERS, WORLDWIDE, THROUGH 2011 (\$ MILLIONS)</i> .....	117
<i>FIGURE 15 THE MARKET FOR LEADING ORPHAN DRUGS TO TREAT NEUROLOGICAL DISEASES AND DISORDERS, WORLDWIDE, 2005-2011 (\$ MILLIONS)</i> .....	118
REPRODUCTIVE DISEASES AND DISORDERS .....	118
AMENORRHEA .....	118
PRECOCIOUS PUBERTY .....	119
IMPAIRED SPERMATOGENESIS .....	119
ORPHAN PRODUCTS APPROVED TO TREAT REPRODUCTIVE DISEASES .....	119
<i>TABLE 54 APPROVED ORPHAN DRUGS TO TREAT REPRODUCTIVE DISEASES AND DISORDERS</i> .....	120
SALES OF LEADING ORPHAN PRODUCTS TO TREAT REPRODUCTIVE DISEASES AND DISORDERS .....	120
<i>TABLE 55 THE MARKET FOR LEADING ORPHAN DRUGS TO TREAT, REPRODUC-TIVE DISEASES AND DISORDERS, WORLDWIDE, THROUGH 2011 (\$ MILLIONS)</i> .....	121
<i>FIGURE 16 THE MARKET FOR LEADING ORPHAN DRUGS TO TREAT REPRODUCTIVE DISEASES AND DISORDERS, WORLDWIDE, 2005-2011 (\$ MILLIONS)</i> .....	121
RESPIRATORY DISEASES .....	121
HYALINE MEMBRANE.....	122
MALIGNANT PLEURAL EFFUSION .....	122
PULMONARY HYPERTENSION .....	122
ORPHAN PRODUCTS APPROVED TO TREAT RESPIRATORY DISEASES.....	123
<i>TABLE 56 APPROVED ORPHAN DRUGS FOR RESPIRATORY DISEASES</i> .....	123
SALES OF LEADING ORPHAN PRODUCTS TO TREAT RESPIRATORY DISEASES .....	124
OTHER SELECTED RARE DISEASES AND DISORDERS FOR WHICH ORPHAN PRODUCTS ARE AVAILABLE .....	124
ACROMEGALY .....	124
CHRONIC GRANULOMATOUS DISEASE .....	125
CYSTINOSIS .....	125
HOMOCYSTINURIA .....	125
MASTOCYTOSIS .....	125

PAGET'S DISEASE.....	126
ORPHAN PRODUCTS APPROVED TO TREAT MISCELLANEOUS DISEASES AND DISORDERS .....	126
<i>TABLE 57 APPROVED ORPHAN DRUGS FOR MISCELLANEOUS         INDICATIONS.....</i>	<i>127</i>
<i>TABLE 57 (CONTINUED).....</i>	<i>128</i>
<i>TABLE 57 (CONTINUED).....</i>	<i>129</i>
<i>TABLE 57 (CONTINUED).....</i>	<i>130</i>
SALES OF LEADING ORPHAN PRODUCTS TO TREAT MISCELLANEOUS DISEASES AND DISORDERS .....	130
<i>TABLE 58 THE MARKET FOR LEADING ORPHAN DRUGS TO         TREAT, MISCELLANEOUS DISEASES AND DISORDERS         WORLDWIDE, THROUGH 2011 (\$ MILLIONS).....</i>	<i>131</i>
<i>FIGURE 17 THE MARKET FOR LEADING ORPHAN DRUGS TO         TREAT MISCELLANEOUS DISEASES AND DISORDERS,         WORLDWIDE, 2005-2011 (\$ MILLIONS).....</i>	<i>131</i>
THERAPEUTIC AREAS WITH THE HIGHEST REVENUES FROM ORPHAN DRUGS IN 2006 AND THEIR FUTURE GROWTH PROSPECTS.....	131
<i>TABLE 59 THE MARKET FOR LEADING ORPHAN DRUGS IN KEY         THERAPEUTIC AREAS WORLDWIDE, THROUGH 2011 (\$         MILLIONS).....</i>	<i>132</i>
<i>FIGURE 18 LEADING ORPHAN DRUG SALES WORLDWIDE AND         FORECASTS BY THERAPEUTIC AREAS, 2006 AND 2011 (%).....</i>	<i>133</i>
LEGISLATION AND REGULATORY ENVIRONMENT.....	134
LEGISLATION IN THE U.S. ....	134
RARE DISEASES ACT OF 2007 AND RARE DISEASES ORPHAN PRODUCT DEVELOPMENT ACT OF 2002.....	135
INCENTIVES FOR ORPHAN DRUG DEVELOPMENT IN THE U.S. ....	135
Technical and Administrative Assistance with the Identification and Development of Orphan Products .....	135
Availability of FDA Grants to Cover Clinical trial Expenses .....	136
Exemption from Prescription Drug User Fee Act (PDUFA)—Waiver of Application Fee.....	136
Tax Credits—50% of the Cost of Clinical Trials Undertaken in the U.S.....	136
Market Exclusivity for 7 Years Following Market Approval.....	136
IMPACT OF THE ORPHAN DRUG ACT IN THE PHARMA AND BIOTECH INDUSTRIES .....	136
WAYS TO CIRCUMVENT MARKET EXCLUSIVITY.....	137

SOME IMPORTANT PUBLIC AGENCIES INVOLVED IN ORPHAN DRUG REGULATION AND PROMOTION IN THE U.S. ....	138
<i>TABLE 60 PUBLIC/NON-PROFIT AGENCIES INVOLVED IN ORPHAN DRUG REGULATION AND PROMOTION IN THE U.S.</i> .....	138
LEGISLATION—EUROPEAN UNION.....	138
INCENTIVES FOR ORPHAN DRUG DEVELOPMENT IN THE EU .....	139
Free Protocol Assistance .....	139
Access to a Centralized Community Procedure for Marketing Authorization with a 50% Reduction in the Fee.....	139
10 Years of Post-approval Market Exclusivity .....	139
MAIN PUBLIC AGENCIES INVOLVED IN ORPHAN DRUG REGULATION AND PROMOTION IN THE EU.....	140
<i>TABLE 61 MAIN PUBLIC/NON-PROFIT AGENCIES INVOLVED IN ORPHAN DRUG REGULATION AND PROMOTION IN THE EU</i> .....	140
AVAILABILITY OF ORPHAN DRUGS IN THE MEMBER STATES OF THE EU .....	141
<i>TABLE 62 SUMMARY OF NATIONAL MEASURES ON ORPHAN DRUGS IN EU</i> .....	141
<i>TABLE 62 (CONTINUED)</i> .....	142
<i>TABLE 62 (CONTINUED)</i> .....	143
<i>TABLE 62 (CONTINUED)</i> .....	144
LEGISLATION—JAPAN .....	144
LEGISLATION—AUSTRALIA .....	145
LEGISLATION—SINGAPORE.....	146
LEGISLATION—OTHER COUNTRIES/REGIONS.....	146
TAIWAN .....	146
KOREA .....	147
HONG KONG.....	147
LEGISLATION COMPARISON—SUMMARY.....	147
<i>TABLE 63 COMPARISON OF ORPHAN DRUG LEGISLATION IN THE U.S., EU, AUSTRALIA AND JAPAN</i> .....	148
<i>TABLE 63 (CONTINUED)</i> .....	149
CONCERN ABOUT THE HIGH PRICE OF ORPHAN DRUGS.....	149
CALL FOR MODIFICATIONS OF ORPHAN DRUG LEGISLATION .....	149
CORRELATION BETWEEN MARKET EXCLUSIVITY AND THE HIGH PRICE OF ORPHAN DRUGS.....	150
IMPACT OF BIOGENERICS ON THE ORPHAN DRUGS SECTOR.....	151
FACTORS LEADING TO THE DELAY IN IMPLEMENTING REGULATIONS ON BIOGENERICS.....	152
TECHNOLOGY TRENDS ANALYSIS .....	153
PATENT ANALYSIS .....	153

LEADING ORPHAN DRUGS AND RELATED PATENTS.....	153
<i>TABLE 64 LEADING ORPHAN DRUGS AND THEIR RELEVANT U.S.</i>	
<i>PATENTS.....</i>	<i>154</i>
<i>TABLE 64 (CONTINUED).....</i>	<i>155</i>
<i>TABLE 64 (CONTINUED).....</i>	<i>156</i>
TECHNOLOGY TRENDS ANALYSIS BASED ON ORPHAN DRUG	
APPROVALS.....	156
GENERAL TRENDS.....	156
<i>TABLE 65 BIOLOGICS IN ORPHAN DRUG APPROVALS, 1983-2006.....</i>	<i>157</i>
<i>FIGURE 19 ORPHAN DRUG APPROVAL TRENDS, BIOLOGICS</i>	
<i>VERSUS NON-BIOLOGICS, 1983-2006.....</i>	<i>158</i>
TRENDS BY PRODUCT TYPES.....	158
<i>FIGURE 20 ORPHAN DRUG APPROVALS BY PRODUCT TYPES, 2006</i>	
<i>(%).....</i>	<i>159</i>
CONCLUSIONS OF TECHNICAL TRENDS ANALYSIS.....	160
COMPANY PROFILES .....	161
AMGEN, INC. ....	161
BAYER AG .....	161
BIOGEN IDEC, INC. ....	162
CELGENE CORPORATION .....	163
GENENTECH, INC. ....	163
GENZYME CORPORATION.....	164
HOFFMANN-LA ROCHE, INC.....	164
JOHNSON & JOHNSON .....	165
NOVARTIS INTERNATIONAL AG.....	165
NOVO NOVODISK A/S .....	166
SCHERING-PLOUGH CORPORATION .....	167
SIGMA-TAU PHARMACEUTICALS, INC.....	168
SWEDISH ORPHAN INTERNATIONAL L AB.....	168